Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

“Patients taking compounded tirzepatide injection are going to need to be transitioned to the FDA-approved drug Mounjaro or Zepbound,” Brunner said. “In many instances, it’s going to take ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Mounjaro and Zepbound are both names for the ... Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions on the market. But when the drug ...

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

Eli Lilly, the manufacturer of Mounjaro and Zepbound, has clearly stated that any drugs sold online or elsewhere under the name “tirzepatide,” which contain only tirzepatide, are not FDA ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes ... dose version of the weight-loss drug Wegovy, the FDA said. The FDA confirmed with Eli Lilly that ...

Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list.Yahoo Finance Senior Health Reporter Anjalee Khemlani ...

Lilly has assured regulators that product availability and manufacturing capacity is enough to meet both current and projected demand in the U.S., the FDA said. The drugs, sold as Mounjaro and ...

The FDA has confirmed that the shortage of Mounjaro and Zepbound is “Resolved” as communicated on FDA’s website.” Whether or not it’s readily available, some patients believe price will ...